Analysts Set Expectations for TENX Q1 Earnings

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Analysts at William Blair issued their Q1 2025 EPS estimates for Tenax Therapeutics in a research note issued on Wednesday, March 26th. William Blair analyst M. Phipps expects that the specialty pharmaceutical company will post earnings per share of ($0.19) for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. William Blair also issued estimates for Tenax Therapeutics’ Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.87) EPS and FY2026 earnings at ($0.94) EPS.

Tenax Therapeutics (NASDAQ:TENX) last issued its earnings results on Tuesday, March 25th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.34.

Several other analysts also recently issued reports on the stock. Leerink Partners set a $20.00 price target on shares of Tenax Therapeutics in a research report on Monday, March 10th. StockNews.com began coverage on shares of Tenax Therapeutics in a research report on Friday, March 21st. They set a “sell” rating for the company. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Tenax Therapeutics has an average rating of “Moderate Buy” and an average target price of $18.00.

Tenax Therapeutics Stock Performance

Shares of Tenax Therapeutics stock opened at $6.18 on Friday. Tenax Therapeutics has a 52 week low of $2.77 and a 52 week high of $7.89. The stock has a 50 day moving average price of $6.43 and a two-hundred day moving average price of $5.40. The stock has a market capitalization of $24.50 million, a PE ratio of -1.16 and a beta of 2.20.

Institutional Investors Weigh In On Tenax Therapeutics

Institutional investors have recently bought and sold shares of the stock. Vestal Point Capital LP purchased a new position in Tenax Therapeutics during the 3rd quarter worth $288,000. Sphera Funds Management LTD. bought a new position in shares of Tenax Therapeutics during the third quarter valued at about $101,000. Two Sigma Investments LP purchased a new position in Tenax Therapeutics during the fourth quarter worth about $84,000. Millennium Management LLC bought a new stake in Tenax Therapeutics in the 4th quarter worth about $166,000. Finally, Janus Henderson Group PLC purchased a new stake in Tenax Therapeutics in the 4th quarter valued at about $1,026,000. Institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.